Edition:
United States

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.91EUR
11:38am EST
Change (% chg)

€0.36 (+0.47%)
Prev Close
€76.55
Open
€76.84
Day's High
€77.85
Day's Low
€76.73
Volume
2,832,186
Avg. Vol
2,475,795
52-wk High
€80.44
52-wk Low
€62.88

Latest Key Developments (Source: Significant Developments)

Sanofi's fexinidazole product has been recommended by European Medicines Agency
Friday, 16 Nov 2018 05:57am EST 

Nov 16 (Reuters) - Sanofi SA ::* European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness .* Move will support international efforts to eliminate sleeping sickness, a fatal neglected tropical disease endemic to Africa, adds Sanofi .  Full Article

Berkshire Hathaway Takes Stake In JPMorgan, Oracle; Exits Walmart
Wednesday, 14 Nov 2018 04:39pm EST 

Nov 14 (Reuters) - Berkshire Hathaway Inc ::BERKSHIRE HATHAWAY INC TAKES SHARE STAKE IN JPMORGAN- SEC FILING.BERKSHIRE HATHAWAY INC TAKES SHARE STAKE IN ORACLE - SEC FILING.BERKSHIRE HATHAWAY INC TAKES SHARE STAKE IN TRAVELERS COMPANIES INC - SEC FILING.BERKSHIRE HATHAWAY INC DISSOLVES SHARE STAKE IN WALMART - SEC FILING.BERKSHIRE HATHAWAY INC DISSOLVES SHARE STAKE OF SPONSORED ADR IN SANOFI - SEC FILING.BERKSHIRE HATHAWAY INC UPS SHARE STAKE IN U.S. BANCORP BY 24.1 PERCENT TO 124.9 MILLION SHARES.BERKSHIRE HATHAWAY INC UPS SHARE STAKE IN BANK OF NEW YORK MELLON BY 20.1 PERCENT TO 77.8 MILLION SHARES.BERKSHIRE HATHAWAY INC TAKES SHARE STAKE IN JPMORGAN OF 35.7 MILLION SHARES - SEC FILING.BERKSHIRE HATHAWAY INC TAKES SHARE STAKE IN ORACLE OF 41.4 MILLION SHARES.BERKSHIRE HATHAWAY INC TAKES SHARE STAKE IN TRAVELERS COMPANIES INC OF 3.5 MILLION SHARES.CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

FDA Grants Priority Review For Dupixent As Potential Treatment For Adolescents With Uncontrolled Moderate-To-Severe Atopic Dermatitis
Tuesday, 6 Nov 2018 08:00am EST 

Nov 6 (Reuters) - Sanofi SA ::FDA GRANTS PRIORITY REVIEW FOR DUPIXENT® (DUPILUMAB) AS POTENTIAL TREATMENT FOR ADOLESCENTS WITH UNCONTROLLED MODERATE-TO-SEVERE ATOPIC DERMATITIS.SANOFI - TARGET ACTION DATE FOR FDA DECISION IS MARCH 11, 2019..  Full Article

Regulus Announces Successful Restructuring Of Sanofi Collaboration
Tuesday, 6 Nov 2018 07:30am EST 

Nov 6 (Reuters) - Regulus Therapeutics Inc ::REGULUS ANNOUNCES SUCCESSFUL RESTRUCTURING OF SANOFI COLLABORATION.REGULUS THERAPEUTICS INC - REGULUS IS ELIGIBLE TO RECEIVE APPROXIMATELY $7 MILLION IN UPFRONT AND MATERIAL TRANSFER PAYMENTS..REGULUS THERAPEUTICS - UNDER TERMS OF AMENDMENT, CO IS ELIGIBLE TO RECEIVE ABOUT $7 MILLION IN UPFRONT AND MATERIAL TRANSFER PAYMENTS.REGULUS THERAPEUTICS INC - SANOFI WILL ASSUME DEVELOPMENT OF RG-012 FOR ALPORT SYNDROME.REGULUS THERAPEUTICS INC - REGULUS IS ALSO ELIGIBLE TO RECEIVE UP TO $40 MILLION IN DEVELOPMENT MILESTONE PAYMENTS.REGULUS THERAPEUTICS - SANOFI WILL REIMBURSE CO FOR CERTAIN OUT-OF-POCKET TRANSITION ACTIVITIES & ASSUME CO'S UPSTREAM LICENSE ROYALTY OBLIGATIONS.REGULUS - SANOFI TO ASSUME ALL FUTURE COSTS AND DEVELOPMENT ACTIVITIES ASSOCIATED WITH ADVANCEMENT OF RG-012, CURRENTLY IN PHASE 2 FOR ALPORT SYNDROME.  Full Article

FDA Grants Priority Review For Sanofi's Dengue Vaccine Candidate
Tuesday, 30 Oct 2018 05:12pm EDT 

Oct 30 (Reuters) - Sanofi SA ::FDA GRANTS PRIORITY REVIEW FOR SANOFI'S DENGUE VACCINE CANDIDATE.SANOFI - FDA HAS ACCEPTED A BIOLOGICS LICENSE APPLICATION FOR SANOFI PASTEUR'S DENGUE VACCINE.SANOFI - FDA SET A PRESCRIPTION DRUG USER FEE ACT ACTION DATE OF MAY 1 FOR SANOFI PASTEUR'S DENGUE VACCINE.SANOFI - EUROPEAN COMMISSION IS EXPECTED TO GRANT MARKETING AUTHORIZATION FOR DENGVAXIA IN DEC 2018.  Full Article

FDA approves asthma indication for Dupixent (dupilumab)
Friday, 19 Oct 2018 05:58pm EDT 

Oct 19 (Reuters) - Sanofi SA ::SANOFI - FDA APPROVES DUPIXENT AS MAINTENANCE THERAPY IN ASTHMA PATIENTS 12 YRS, OLDER WITH EOSINOPHILIC PHENOTYPE/ORAL CORTICOSTEROID-DEPENDENT ASTHMA.  Full Article

Sanofi to launch new Primary Care and China/Emerging Market business units
Thursday, 13 Sep 2018 06:10am EDT 

Sept 13 (Reuters) - Sanofi SA ::* To refocus two global business units (GBU).* Will create new Primary Care GBU that combines the product portfolios of Sanofi's existing Diabetes and Cardiovascular (DCV) GBU with Established Products, which are currently part of the General Medicines & Emerging Markets (GEM) GBU.* Creating a second new global business unit called China & Emerging Markets to be led by Olivier Charmeil, currently head of the GEM GBU..* Dieter Weinand to lead new Primary Care business unit.* Stefan Oelrich, currently head of the DCV GBU, has decided to leave Sanofi and will join Bayer AG .* Sanofi expects to launch the new Primary Care and China & Emerging Markets global business units by the beginning of 2019.  Full Article

U.S. FDA to review supplemental Biologics License Application for Praluent®
Wednesday, 12 Sep 2018 01:00am EDT 

Sept 12 (Reuters) - Sanofi SA ::* U.S. Food & Drug Administration (FDA) to review supplemental Biologics License Application for Praluent(®) (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events.* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy.* Praluent is being developed by Regeneron and Sanofi under a global collaboration agreement.  Full Article

Regeneron Says U.S. FDA Accepted Supplemental Biologics License Application For Praluent(Alirocumab) Injection
Wednesday, 12 Sep 2018 12:59am EDT 

Sept 12 (Reuters) - Regeneron Pharmaceuticals Inc ::FDA TO REVIEW SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR PRALUENT® (ALIROCUMAB)INJECTION AS POTENTIAL TREATMENT TO REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS.REGENERON PHARMACEUTICALS -CO, SANOFI ANNOUNCED THAT U.S. FDA ACCEPTED SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR PRALUENT(ALIROCUMAB) INJECTION.FDA SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF APRIL 28, 2019.  Full Article

Dyadic International Announces Research Collaboration With Sanofi-Aventis
Friday, 7 Sep 2018 11:18am EDT 

Sept 7 (Reuters) - Dyadic International Inc ::DYADIC INTERNATIONAL ANNOUNCES RESEARCH COLLABORATION WITH SANOFI-AVENTIS.DYADIC INTERNATIONAL - ENTERED INTO FULLY FUNDED RESEARCH COLLABORATION TO EXPLORE POTENTIAL OF ITS C1 TECHNOLOGY WITH SANOFI-AVENTIS DEUTSCHLAND GMBH.DYADIC INTERNATIONAL INC - OTHER TERMS OF RESEARCH COLLABORATION ARE CONFIDENTIAL.  Full Article

Boehringer Ingelheim plans to cut about 300 jobs in France

PARIS, Dec 10 German drugmaker Boehringer Ingelheim told unions on Monday that it plans to cut some 300 jobs in France as part of efforts to reorganise activities around its hub in Lyon following an asset swap with Sanofi in 2017.